A. Claeys

发表

Benchmark of tools for in silico prediction of MHC class I and class II genotypes from NGS data

K. Marchal, J. Van den Eynden, A. Claeys, 2022, bioRxiv.

A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues

A. Vral, E. Larsson, T. Lammens, 2022, Scientific Reports.

Benchmark of tools for in silico prediction of MHC class I and class II genotypes from NGS data

K. Marchal, J. Van den Eynden, A. Claeys, 2022, bioRxiv.

Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals

K. Marchal, J. Van den Eynden, A. Claeys, 2021, PLoS genetics.

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

R. Palmer, B. Hallberg, G. Umapathy, 2021, Nature Communications.

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

T. Masudi, J. Koster, R. Palmer, 2021, The EMBO journal.

A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in histologically healthy tissues

A. Vral, E. Larsson, T. Lammens, 2022, bioRxiv.

Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution-Letter.

J. Van den Eynden, A. Claeys, 2023, Cancer research.

Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN

R. Palmer, B. Hallberg, J. Siaw, 2023, bioRxiv.

Benchmark of tools for in silico prediction of MHC class I and class II genotypes from NGS data

K. Marchal, J. Van den Eynden, A. Claeys, 2023, BMC Genomics.